Skip to main content
Erschienen in: Osteoporosis International 2/2013

01.02.2013 | Original Article

Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures

verfasst von: F. Lapi, F. Cipriani, A. P. Caputi, G. Corrao, A. Vaccheri, M. C. Sturkenboom, M. Di Bari, D. Gregori, F. Carle, T. Staniscia, A. Vestri, M. Brandi, V. Fusco, G. Campisi, G. Mazzaglia, on behalf of the Bisphosphonates Efficacy-Safety Tradeoff (BEST) study group

Erschienen in: Osteoporosis International | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Summary

There is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Although the occurrence of ONJ appears rare among oral bisphosphonates (BPs) users, it is important to know that it exists and can be opportunely minimized.

Introduction

The purpose of this study is to evaluate the association between BPs prescribed for the secondary prevention of osteoporotic fractures and the occurrence of ONJ.

Methods

An Italian record linkage claims database with a target population of around 18 million individuals (6 million over 55 years of age) constituted the data source. We conducted a nested case–control study within a cohort of individuals aged 55+ years old, who were discharged from hospitals with a primary diagnosis of incident osteoporotic fracture. The date related to the discharge diagnosis of ONJ was the index date. Conditional logistic regression for matched data was fitted to estimate the odds ratio (OR) along with 95 % confidence intervals (95 % CI) for the likely association between use of BPs and the risk of ONJ.

Results

Any one of the 61 ascertained cases of ONJ (incidence rate, 36.6 per 100,000 person-years) was matched to 20 controls for a total of 1120 controls. When the exposure to BPs was modeled according to recency (i.e., exposure time window prior to the index date) of use, the adjusted OR (95 % CI) for current users was 2.8 (1.3–5.9) against never users. The cumulative use of BPs has shown to increase the incidence of ONJ among patients with primary osteoporotic fractures, although not statistically significant risk has been observed.

Conclusions

Although the risk of BP-related ONJ appears low in non-oncological indications, it is important to be aware that it exists and to know how it may be predicted and possibly minimized.
Literatur
1.
Zurück zum Zitat Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMed Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMed
2.
Zurück zum Zitat Khosla S, Burr D, Cauley J et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491PubMedCrossRef Khosla S, Burr D, Cauley J et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491PubMedCrossRef
3.
Zurück zum Zitat Migliorati CA (2003) Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253–4254PubMedCrossRef Migliorati CA (2003) Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253–4254PubMedCrossRef
4.
Zurück zum Zitat Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117PubMedCrossRef Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117PubMedCrossRef
5.
Zurück zum Zitat Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg 67:2–12PubMed Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg 67:2–12PubMed
6.
Zurück zum Zitat Khan AA, Sandor GK, Dore E et al (2008) Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35:1391–1397PubMed Khan AA, Sandor GK, Dore E et al (2008) Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35:1391–1397PubMed
7.
Zurück zum Zitat Assael LA (2009) Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg 67:35–43PubMedCrossRef Assael LA (2009) Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg 67:35–43PubMedCrossRef
8.
Zurück zum Zitat Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534PubMedCrossRef Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534PubMedCrossRef
9.
Zurück zum Zitat Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575PubMedCrossRef Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575PubMedCrossRef
10.
Zurück zum Zitat Sarasquete ME, Gonzalez M, San Miguel JF, Garcia-Sanz R (2009) Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 15:382–387PubMedCrossRef Sarasquete ME, Gonzalez M, San Miguel JF, Garcia-Sanz R (2009) Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 15:382–387PubMedCrossRef
11.
Zurück zum Zitat Marini F, Tonelli P, Cavalli L, Cavalli T, Masi L, Falchetti A, Brandi ML (2011) Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Front Biosci (EliteEd) 3:364–370CrossRef Marini F, Tonelli P, Cavalli L, Cavalli T, Masi L, Falchetti A, Brandi ML (2011) Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Front Biosci (EliteEd) 3:364–370CrossRef
12.
Zurück zum Zitat Fusco V, Loidoris A, Colella G, Vescovi P, Campisi G (2010) Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment. Breast 19:432–433PubMedCrossRef Fusco V, Loidoris A, Colella G, Vescovi P, Campisi G (2010) Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment. Breast 19:432–433PubMedCrossRef
13.
Zurück zum Zitat Vescovi P, Campisi G, Fusco V et al (2011) Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol 47:191–194PubMedCrossRef Vescovi P, Campisi G, Fusco V et al (2011) Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol 47:191–194PubMedCrossRef
14.
Zurück zum Zitat Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415–423PubMedCrossRef Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415–423PubMedCrossRef
15.
Zurück zum Zitat Bilezikian JP (2006) Osteonecrosis of the jaw—do bisphosphonates pose a risk? N Engl J Med 355:2278–2281PubMedCrossRef Bilezikian JP (2006) Osteonecrosis of the jaw—do bisphosphonates pose a risk? N Engl J Med 355:2278–2281PubMedCrossRef
16.
Zurück zum Zitat Edwards BJ, Gounder M, McKoy JM et al (2008) Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9:1166–1172PubMedCrossRef Edwards BJ, Gounder M, McKoy JM et al (2008) Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9:1166–1172PubMedCrossRef
17.
Zurück zum Zitat Jung TI, Hoffmeister B (2007) Osteonecrosis of jaw under bisphosphonate therapy: patient profile and risk assessment. J Bone Miner Res 22:S113–S113 Jung TI, Hoffmeister B (2007) Osteonecrosis of jaw under bisphosphonate therapy: patient profile and risk assessment. J Bone Miner Res 22:S113–S113
18.
Zurück zum Zitat Lo JC, O’Ryan FS, Gordon NP et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68:243–253PubMedCrossRef Lo JC, O’Ryan FS, Gordon NP et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68:243–253PubMedCrossRef
19.
Zurück zum Zitat Zavras AI, Zhu S (2006) Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 64:917–923PubMedCrossRef Zavras AI, Zhu S (2006) Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 64:917–923PubMedCrossRef
20.
Zurück zum Zitat Pazianas M, Blumentals W, Miller P (2008) Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int 19:773–779PubMedCrossRef Pazianas M, Blumentals W, Miller P (2008) Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int 19:773–779PubMedCrossRef
21.
Zurück zum Zitat Barasch A, Cunha-Cruz J, Curro FA et al (2011) Risk factors for osteonecrosis of the jaws: a case–control study from the CONDOR dental PBRN. J Dent Res 90:439–444PubMedCrossRef Barasch A, Cunha-Cruz J, Curro FA et al (2011) Risk factors for osteonecrosis of the jaws: a case–control study from the CONDOR dental PBRN. J Dent Res 90:439–444PubMedCrossRef
22.
Zurück zum Zitat Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Sogaard AJ (2010) Prescription of anti-osteoporosis drugs during 2004–2007—a nationwide register study in Norway. Eur J Clin Pharmacol 66:299–306PubMedCrossRef Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Sogaard AJ (2010) Prescription of anti-osteoporosis drugs during 2004–2007—a nationwide register study in Norway. Eur J Clin Pharmacol 66:299–306PubMedCrossRef
23.
Zurück zum Zitat Piscitelli P, Gimigliano F, Gatto S et al (2009) Hip fractures in Italy: 2000–2005 extension study. Osteoporos Int 21:1323–1330PubMedCrossRef Piscitelli P, Gimigliano F, Gatto S et al (2009) Hip fractures in Italy: 2000–2005 extension study. Osteoporos Int 21:1323–1330PubMedCrossRef
24.
Zurück zum Zitat Lapi F, Simonetti M, Michieli R, Pasqua A, Brandi ML, Frediani B, Cricelli C, Mazzaglia G (2011) Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary care. Bone 50:85–90PubMedCrossRef Lapi F, Simonetti M, Michieli R, Pasqua A, Brandi ML, Frediani B, Cricelli C, Mazzaglia G (2011) Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary care. Bone 50:85–90PubMedCrossRef
25.
Zurück zum Zitat Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG (2009) Identification and validation of vertebral compression fractures using administrative claims data. Med Care 47:69–72PubMedCrossRef Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG (2009) Identification and validation of vertebral compression fractures using administrative claims data. Med Care 47:69–72PubMedCrossRef
26.
Zurück zum Zitat Curtis JR, Taylor AJ, Matthews RS et al (2009) "Pathologic" fractures: should these be included in epidemiologic studies of osteoporotic fractures? Osteoporos Int 20:1969–1972PubMedCrossRef Curtis JR, Taylor AJ, Matthews RS et al (2009) "Pathologic" fractures: should these be included in epidemiologic studies of osteoporotic fractures? Osteoporos Int 20:1969–1972PubMedCrossRef
27.
Zurück zum Zitat Austin PC (2008) The performance of different propensity-score methods for estimating relative risks. J Clin Epidemiol 61:537–545PubMedCrossRef Austin PC (2008) The performance of different propensity-score methods for estimating relative risks. J Clin Epidemiol 61:537–545PubMedCrossRef
28.
Zurück zum Zitat Patrick AR, Schneeweiss S, Brookhart MA, Glynn RJ, Rothman KJ, Avorn J, Sturmer T (2011) The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf 20:551–559PubMedCrossRef Patrick AR, Schneeweiss S, Brookhart MA, Glynn RJ, Rothman KJ, Avorn J, Sturmer T (2011) The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf 20:551–559PubMedCrossRef
29.
Zurück zum Zitat Etminan M, Aminzadeh K, Matthew IR, Brophy JM (2008) Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case–control study. J Rheumatol 35:691–695PubMed Etminan M, Aminzadeh K, Matthew IR, Brophy JM (2008) Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case–control study. J Rheumatol 35:691–695PubMed
30.
Zurück zum Zitat Beiderbeck AB, Sturkenboom MC, Coebergh JW, Leufkens HG, Stricker BH (2004) Misclassification of exposure is high when interview data on drug use are used as a proxy measure of chronic drug use during follow-up. J Clin Epidemiol 57:973–977PubMedCrossRef Beiderbeck AB, Sturkenboom MC, Coebergh JW, Leufkens HG, Stricker BH (2004) Misclassification of exposure is high when interview data on drug use are used as a proxy measure of chronic drug use during follow-up. J Clin Epidemiol 57:973–977PubMedCrossRef
31.
Zurück zum Zitat Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J, Bauss F, Ehrenfeld M, Schieker M (2010) Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 68:2837–2845PubMedCrossRef Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J, Bauss F, Ehrenfeld M, Schieker M (2010) Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 68:2837–2845PubMedCrossRef
32.
Zurück zum Zitat Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86:1022–1033PubMedCrossRef Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86:1022–1033PubMedCrossRef
33.
Zurück zum Zitat Hughes DE, MacDonald BR, Russell RG, Gowen M (1989) Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83:1930–1935PubMedCrossRef Hughes DE, MacDonald BR, Russell RG, Gowen M (1989) Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83:1930–1935PubMedCrossRef
34.
Zurück zum Zitat Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gligorov J, Vaananen K, Pylkkanen L, Pecherstorfer M, Aapro MS (2007) Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: is there a diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol Hematol 64:198–207PubMedCrossRef Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gligorov J, Vaananen K, Pylkkanen L, Pecherstorfer M, Aapro MS (2007) Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: is there a diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol Hematol 64:198–207PubMedCrossRef
35.
Zurück zum Zitat Delmas PD, Siris ES (2008) NICE recommendations for the prevention of osteoporotic fractures in postmenopausal women. Bone 42:16–18PubMedCrossRef Delmas PD, Siris ES (2008) NICE recommendations for the prevention of osteoporotic fractures in postmenopausal women. Bone 42:16–18PubMedCrossRef
36.
Zurück zum Zitat Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022PubMedCrossRef Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022PubMedCrossRef
Metadaten
Titel
Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures
verfasst von
F. Lapi
F. Cipriani
A. P. Caputi
G. Corrao
A. Vaccheri
M. C. Sturkenboom
M. Di Bari
D. Gregori
F. Carle
T. Staniscia
A. Vestri
M. Brandi
V. Fusco
G. Campisi
G. Mazzaglia
on behalf of the Bisphosphonates Efficacy-Safety Tradeoff (BEST) study group
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 2/2013
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-012-2013-y

Weitere Artikel der Ausgabe 2/2013

Osteoporosis International 2/2013 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.